

Transforming the journey for HER2+ breast cancer patients



Friday 2 December 2022, 12:45–14:15 SGT

Hall 407, Level 4, Suntec Singapore Convention & Exhibition Centre, Singapore

Please join us for an interesting and interactive session to explore how the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) has helped to optimise treatment of HER2-positive breast cancer beyond efficacy. We will then discuss how flexible care can optimise the treatment experience for patients with breast cancer and positively impact healthcare systems.

We look forward to seeing you in Singapore or via the live stream!



Prof. Wang Shu
Peking University
People's Hospital, China



Prof. Christian Jackisch
Sana Klinikum Offenbach,
Germany



Dr Elaine Lim
National Cancer Centre,
Singapore

Programme

Introduction	Dr Elaine Lim
Transforming the experience of patients with HER2-positive BC with recent clinical trials of PH FDC SC	Prof. Wang Shu
Value of subcutaneous treatment options for the healthcare system: Introducing Flexible Care as an opportunity to bring treatment closer to patients	Prof. Christian Jackisch
NCCS Homecare: Delivering cancer care at home	Dr Elaine Lim
Q&A	All faculty
Summary and close	Prof. Christian Jackisch

Lunch will be served during this meeting